221 related articles for article (PubMed ID: 20080792)
1. EBNA1 regulates cellular gene expression by binding cellular promoters.
Canaan A; Haviv I; Urban AE; Schulz VP; Hartman S; Zhang Z; Palejev D; Deisseroth AB; Lacy J; Snyder M; Gerstein M; Weissman SM
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22421-6. PubMed ID: 20080792
[TBL] [Abstract][Full Text] [Related]
2. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
3. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).
Lu F; Wikramasinghe P; Norseen J; Tsai K; Wang P; Showe L; Davuluri RV; Lieberman PM
Virol J; 2010 Oct; 7():262. PubMed ID: 20929547
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
7. Intracellular forms of human NOTCH1 functionally activate essential Epstein-Barr virus major latent promoters in the Burkitt's lymphoma BJAB cell line but repress these promoters in Jurkat cells.
Cotter M; Callahan J; Aster J; Robertson E
J Virol; 2000 Feb; 74(3):1486-94. PubMed ID: 10627560
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.
Murakami M; Lan K; Subramanian C; Robertson ES
J Virol; 2005 Feb; 79(3):1559-68. PubMed ID: 15650182
[TBL] [Abstract][Full Text] [Related]
9. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
10. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells.
Wang L; Laing J; Yan B; Zhou H; Ke L; Wang C; Narita Y; Zhang Z; Olson MR; Afzali B; Zhao B; Kazemian M
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999023
[TBL] [Abstract][Full Text] [Related]
12. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
Schaefer BC; Strominger JL; Speck SH
Mol Cell Biol; 1997 Jan; 17(1):364-77. PubMed ID: 8972217
[TBL] [Abstract][Full Text] [Related]
13. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
15. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
16. Ribosome Protein L4 is essential for Epstein-Barr Virus Nuclear Antigen 1 function.
Shen CL; Liu CD; You RI; Ching YH; Liang J; Ke L; Chen YL; Chen HC; Hsu HJ; Liou JW; Kieff E; Peng CW
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2229-34. PubMed ID: 26858444
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.
Lu J; Murakami M; Verma SC; Cai Q; Haldar S; Kaul R; Wasik MA; Middeldorp J; Robertson ES
Virology; 2011 Feb; 410(1):64-75. PubMed ID: 21093004
[TBL] [Abstract][Full Text] [Related]
18. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
19. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection.
Zetterberg H; Stenglein M; Jansson A; Ricksten A; Rymo L
J Gen Virol; 1999 Feb; 80 ( Pt 2)():457-466. PubMed ID: 10073708
[TBL] [Abstract][Full Text] [Related]
20. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
Taylor KA; Wetzel S; Lyles DS; Pollok BA
J Virol; 1994 Oct; 68(10):6421-31. PubMed ID: 8083980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
